

Ke d : DA pathways; Mesocortical; Nigrostrial; Tuberoinfundibular; Mesolimbic pathways; Antipsychotics

Journal of Palliative Care & Medicine

I dci

Opinion

Schizophrenia is a group of related disorders that is similar to organic brain syndromes and manic-depressive illness. However, unlike organic brain syndromes, the causes of schizophrenia likely involve changes at the cellular level in the brain, rather than larger structural changes. e exact mechanisms that lead to schizophrenia are not yet fully understood, but may involve changes in neurotransmitters, neuroreceptors, connections between brain cells, or the structure and function of small organelles within brain cells. Studies of families and identical twins suggest that genetics plays a signi cant role in the development of schizophrenia, but the speci c genes involved are likely to be many and complex. e lifetime risk of developing schizophrenia is about 0.5% across all populations studied. Schizophrenia is a disorder of thinking that causes fragmentation of mental function. It impairs the brain's ability to organize concepts and assemble information into coherent ideas, a ecting all aspects of information processing.

is includes cognition, emotional reactions, sensory information, and behavior, resulting in a fragmented and bizarre presentation of self in everyday life. e patient's narrative is di cult to understand and may contain fragments of opposite ideas without explanation. Psychotic symptoms such as hallucinations and delusions also exhibit Citation: Qizi UXU (2023) Symptoms with Decreasing amount of Dopamine in Schizophrenia. J Palliat Care Med 13: 497.

e ective to treatment of schizophrenia. However, like typical antipsychotics, they have enough side e ects. is group of drugs consist of aripiprazole, clozapine, lurasidone, olanzapine that block both D2 receptors and 5-HT2A receptors in the brain as a result serotonin receptors may increase dopamine levels in brain areas that is modest D2 receptor blockade combination with serotonin need it. receptor blockade is thought signi cantly lower the incidence of extrapyramidal side e ects as well as reduce negative symptoms [9]. Atypical drugs can also bind too many other targets including other subtypes of serotonin receptors as well as histamine, muscarinic and alpha-adrenergic receptors. is may lead to increase more side e ects such as weight gain and hyperlipidemia caused by blockade the subtypes of serotonin receptors. In addition, other atypical antipsychotics such as clozapine and olanzapine may lead to contribute weight gain and sedation due to blind H1 receptors. Agents that have signi cant a nity for alpha-adrenergic receptors may cause orthostatic hypotension. One atypical agent clozapine can cause condition that are more serious called agranulocytosis that occurs when bone narrow does not produce enough white blood cells to blood.

C cl i

Dopamine pathways are more important for treatment of schizophrenia, because there may be various symptoms in patients. e most signi cant thing is overdosage of antipsychotics may cause increase

of all symptoms that is why we should choose the most appropriate drugs to treat with drugs more successfully in schizophrenia.

References

Page 2 of 2